Abbott’s STARLIMS Business Acquires Distribution Partners to Build International Presence
News May 12, 2012
As part of a series of strategic moves to build its laboratory
information management system (LIMS) business in Europe and emerging
markets in Latin America and Africa, STARLIMS Technologies, an Abbott
company, has announced the acquisition of several longtime distribution
These acquisitions include STARLIMS's French distributor Varilab; operations of two privately held Spanish businesses, now operating as STARLIMS Iberica; a privately held Dutch company, now operating as STARLIMS Netherlands, with a branch office in Solna, Sweden; and the business of its Israeli distribution partner, STARLIMS Israel, Ltd. In addition, the company established STARLIMS Germany GmbH, with offices in Witten, Germany, to provide direct support for its German and Swiss customers.
"The successful completion of these transactions represents Abbott's commitment to invest in and accelerate the growth of STARLIMS's core business," said Isaac Friedman, head of Abbott's STARLIMS business. "With these acquisitions, we now have more than 100 experienced LIMS engineers in the region allowing us to better serve our fast-growing European customer base and further strengthen our position as a leading provider of laboratory information management systems in Europe and other important markets."
Since its acquisition by Abbott in March 2010, STARLIMS has accelerated its worldwide sales growth and R&D spending. This has resulted in the addition of more than 150 customers across its global operations including major government accounts in the fields of forensics, public health and utilities, as well as multinational manufacturing and pharmaceutical companies.
Scientists at Tokyo Tech, Ricoh co. and The National Institute of Advanced Industrial Science and Technology have developed an ultra-low-power atomic clock (ULPAC) for small satellites to enable future communication systems beyond 5G. The proposed device outperforms the current industry standards in various benchmarks, such as size, stability, and power consumption.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE